S&P 500   4,274.51
DOW   33,550.27
QQQ   355.04
Cintas: A Quality Buy and Hold Forever Stock at Any Price
66,000% upside on tiny biotech? (Ad)
Pain for Gain: 2 Stocks Whose CEOs Left Without a Clue
3 Household Names With RSIs That Scream Oversold
66,000% upside on tiny biotech? (Ad)
The Odds Are High Costco Will Declare a Special Dividend Soon 
Stock market today: Global shares mostly fall over China worries
66,000% upside on tiny biotech? (Ad)
This Little Known Automaker May Save Your Life and Your Portfolio
How You Can Reverse Engineer Michael Burry's Latest Buy
S&P 500   4,274.51
DOW   33,550.27
QQQ   355.04
Cintas: A Quality Buy and Hold Forever Stock at Any Price
66,000% upside on tiny biotech? (Ad)
Pain for Gain: 2 Stocks Whose CEOs Left Without a Clue
3 Household Names With RSIs That Scream Oversold
66,000% upside on tiny biotech? (Ad)
The Odds Are High Costco Will Declare a Special Dividend Soon 
Stock market today: Global shares mostly fall over China worries
66,000% upside on tiny biotech? (Ad)
This Little Known Automaker May Save Your Life and Your Portfolio
How You Can Reverse Engineer Michael Burry's Latest Buy
S&P 500   4,274.51
DOW   33,550.27
QQQ   355.04
Cintas: A Quality Buy and Hold Forever Stock at Any Price
66,000% upside on tiny biotech? (Ad)
Pain for Gain: 2 Stocks Whose CEOs Left Without a Clue
3 Household Names With RSIs That Scream Oversold
66,000% upside on tiny biotech? (Ad)
The Odds Are High Costco Will Declare a Special Dividend Soon 
Stock market today: Global shares mostly fall over China worries
66,000% upside on tiny biotech? (Ad)
This Little Known Automaker May Save Your Life and Your Portfolio
How You Can Reverse Engineer Michael Burry's Latest Buy
S&P 500   4,274.51
DOW   33,550.27
QQQ   355.04
Cintas: A Quality Buy and Hold Forever Stock at Any Price
66,000% upside on tiny biotech? (Ad)
Pain for Gain: 2 Stocks Whose CEOs Left Without a Clue
3 Household Names With RSIs That Scream Oversold
66,000% upside on tiny biotech? (Ad)
The Odds Are High Costco Will Declare a Special Dividend Soon 
Stock market today: Global shares mostly fall over China worries
66,000% upside on tiny biotech? (Ad)
This Little Known Automaker May Save Your Life and Your Portfolio
How You Can Reverse Engineer Michael Burry's Latest Buy
NASDAQ:LBPH

Longboard Pharmaceuticals (LBPH) Competitors

$5.55
-0.05 (-0.89%)
(As of 09/27/2023 ET)
Compare
Today's Range
$5.42
$5.89
50-Day Range
$5.55
$7.49
52-Week Range
$2.70
$10.29
Volume
17,437 shs
Average Volume
49,677 shs
Market Capitalization
$127.54 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.40

LBPH vs. AADI, PBYI, IFRX, BIVI, ANNX, XBIT, ALT, DBTX, SBTX, and DSGN

Should you be buying Longboard Pharmaceuticals stock or one of its competitors? The main competitors of Longboard Pharmaceuticals include Aadi Bioscience (AADI), Puma Biotechnology (PBYI), InflaRx (IFRX), BioVie (BIVI), Annexon (ANNX), XBiotech (XBIT), Altimmune (ALT), Decibel Therapeutics (DBTX), Silverback Therapeutics (SBTX), and Design Therapeutics (DSGN). These companies are all part of the "pharmaceutical preparations" industry.

Longboard Pharmaceuticals vs.

Longboard Pharmaceuticals (NASDAQ:LBPH) and Aadi Bioscience (NASDAQ:AADI) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, community ranking, earnings, institutional ownership, risk and profitability.

63.3% of Longboard Pharmaceuticals shares are owned by institutional investors. Comparatively, 58.3% of Aadi Bioscience shares are owned by institutional investors. 5.6% of Longboard Pharmaceuticals shares are owned by company insiders. Comparatively, 35.8% of Aadi Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Longboard Pharmaceuticals presently has a consensus price target of $17.40, indicating a potential upside of 213.51%. Aadi Bioscience has a consensus price target of $39.00, indicating a potential upside of 647.13%. Given Aadi Bioscience's higher probable upside, analysts plainly believe Aadi Bioscience is more favorable than Longboard Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Longboard Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
3.00
Aadi Bioscience
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Longboard Pharmaceuticals has a beta of 1.25, meaning that its stock price is 25% more volatile than the S&P 500. Comparatively, Aadi Bioscience has a beta of 1.09, meaning that its stock price is 9% more volatile than the S&P 500.

In the previous week, Longboard Pharmaceuticals and Longboard Pharmaceuticals both had 2 articles in the media. Longboard Pharmaceuticals' average media sentiment score of 1.44 beat Aadi Bioscience's score of 0.42 indicating that Longboard Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
Longboard Pharmaceuticals Positive
Aadi Bioscience Neutral

Longboard Pharmaceuticals received 18 more outperform votes than Aadi Bioscience when rated by MarketBeat users. Likewise, 62.79% of users gave Longboard Pharmaceuticals an outperform vote while only 47.37% of users gave Aadi Bioscience an outperform vote.

CompanyUnderperformOutperform
Longboard PharmaceuticalsOutperform Votes
27
62.79%
Underperform Votes
16
37.21%
Aadi BioscienceOutperform Votes
9
47.37%
Underperform Votes
10
52.63%

Longboard Pharmaceuticals has higher earnings, but lower revenue than Aadi Bioscience. Longboard Pharmaceuticals is trading at a lower price-to-earnings ratio than Aadi Bioscience, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Longboard PharmaceuticalsN/AN/A-$43.94M-$2.55-2.18
Aadi Bioscience$15.22M8.41-$60.51M-$2.44-2.14

Longboard Pharmaceuticals has a net margin of 0.00% compared to Aadi Bioscience's net margin of -285.87%. Aadi Bioscience's return on equity of -40.72% beat Longboard Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Longboard PharmaceuticalsN/A -74.91% -66.49%
Aadi Bioscience -285.87%-40.72%-35.18%

Summary

Longboard Pharmaceuticals beats Aadi Bioscience on 8 of the 15 factors compared between the two stocks.


Get Longboard Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for LBPH and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LBPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

LBPH vs. The Competition

MetricLongboard PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$127.54M$5.79B$4.40B$6.23B
Dividend YieldN/A2.69%2.50%6.54%
P/E Ratio-2.185.39133.6512.29
Price / SalesN/A154.303,003.5057.83
Price / CashN/A22.4992.44100.54
Price / Book1.553.783.734.60
Net Income-$43.94M$200.17M$122.36M$186.23M
7 Day Performance-0.36%-0.53%-0.82%-1.01%
1 Month Performance-6.25%-7.89%-4.15%-5.61%
1 Year Performance61.81%5.46%8.30%3.39%

Longboard Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AADI
Aadi Bioscience
2.1713 of 5 stars
$5.24
+4.6%
$39.00
+644.3%
-60.6%$128.49M$15.22M-2.1589Short Interest ↑
PBYI
Puma Biotechnology
1.8339 of 5 stars
$2.72
-1.8%
$8.00
+194.1%
+18.1%$129.23M$228M-54.40192
IFRX
InflaRx
2.159 of 5 stars
$2.90
-5.2%
$14.00
+382.8%
+14.7%$129.63MN/A-3.7244Positive News
BIVI
BioVie
1.8299 of 5 stars
$3.53
+8.6%
$10.33
+192.7%
+31.8%$129.90MN/A-2.2918Short Interest ↑
High Trading Volume
ANNX
Annexon
1.9927 of 5 stars
$2.45
-1.6%
$14.33
+485.0%
-61.3%$130.44MN/A-1.2477Short Interest ↑
XBIT
XBiotech
0 of 5 stars
$4.16
-0.5%
N/A+11.7%$126.63M$4.01M-3.5084Short Interest ↑
Gap Down
ALT
Altimmune
1.9537 of 5 stars
$2.52
+0.4%
$15.20
+503.2%
-79.4%$132.78M$4.41M-1.5552Short Interest ↑
DBTX
Decibel Therapeutics
2.3218 of 5 stars
$4.91
flat
$8.45
+72.1%
N/A$123.39MN/A-1.9468
SBTX
Silverback Therapeutics
0 of 5 stars
$3.75
+4.2%
N/A-24.7%$135.22MN/A-1.5583Gap Up
High Trading Volume
DSGN
Design Therapeutics
2.4626 of 5 stars
$2.42
+1.7%
$6.20
+156.2%
-84.4%$135.50M$230,000.00-1.8168Short Interest ↑
Positive News

Related Companies and Tools

This page (NASDAQ:LBPH) was last updated on 9/28/2023 by MarketBeat.com Staff

My Account -